Eddies in the North Brazil Current retroflection region observed by Geosat altimetry

Mesoscale fluctuations in the western tropical Atlantic are analyzed in Geosat altimetry sea surface height (SSH) and geostrophic velocity anomalies to investigate the role of eddies in the North Brazil Current (NBC) retroflection zone. The detachment of anticyclonic eddies from the NBC retroflection is observed during November through January, when the NBC retroflection into the North Equatorial Countercurrent (NECC) weakens and finally breaks down. These eddies are traced over more than 2 months between 50° and 60°W on their way toward the Caribbean, at average speeds of 15 cm s−1. In one case an apparent merger of two anticyclonic eddies occurs, one detached from the retroflection zone and one detached from the NECC. Cyclonic eddies are also observed but are generally less persistent. Mesoscale SSH variance just west of the retroflection increases by a factor of 2 from early summer to winter, mainly because of the anticyclonic eddies. Interhemispheric water mass transfer associated with the eddy flux out of the NBC retroflection may amount to an average transport of 3 Sv

Seasonal variations in the western tropical Atlantic: Surface circulation from Geosat altimetry and WOCE model results

Sea level variations and geostrophic circulation in the western tropical Atlantic are studied in an intercomparison of Geosat altimetry and the World Ocean Circulation Experiment community model effort high‐resolution model forced with climatological windstress. Overall, the annual cycles of geostrophic current fields of both products compare very well. Special comparison areas are the western North Equatorial Countercurrent (NECC) and the North Brazil Current (NBC) region. Meridional profiles of zonal velocity anomalies show a seasonal meridional migration of the NECC core centered at 5°N and a weaker eastward maximum during fall at 9°N in both products. The Geosat and model seasonal cycles of the NECC core velocity in the region 35°–45°W are highly correlated and agree with respect to the onset of eastward current acceleration and deceleration in May and December, respectively. Geosat time series from November 1986 to June 1989 show year to year differences, in particular an anomalous early NECC acceleration phase in 1987. In the NBC region 54°–58°W, flow anomalies from both Geosat and the model have two westward maxima, in March and June, which appear to be associated with eastward anomalies further offshore

Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL

Summary: Platform trials bring the promise of making clinical research more efficient and more patient centric. While their use has become more widespread, including their prominent role during the COVID-19 pandemic response, broader adoption of platform trials has been limited by the lack of experience and tools to navigate the critical upfront planning required to launch such collaborative studies. The European Union-Patient-cEntric clinicAl tRial pLatform (EU-PEARL) initiative has produced new methodologies to expand the use of platform trials with an overarching infrastructure and services embedded into Integrated Research Platforms (IRPs), in collaboration with patient representatives and through consultation with U.S. Food and Drug Administration and European Medicines Agency stakeholders. In this narrative review, we discuss the outlook for platform trials in Europe, including challenges related to infrastructure, design, adaptations, data sharing and regulation. Documents derived from the EU-PEARL project, alongside a literature search including PubMed and relevant grey literature (e.g., guidance from regulatory agencies and health technology agencies) were used as sources for a multi-stage collaborative process through which the 10 more important points based on lessons drawn from the EU-PEARL project were developed and summarised as guidance for the setup of platform trials. We conclude that early involvement of critical stakeholder such as regulatory agencies or patients are critical steps in the implementation and later acceptance of platform trials. Addressing these gaps will be critical for attaining the full potential of platform trials for patients. Funding: Innovative Medicines Initiative 2 Joint Undertaking with support from the European Union’s Horizon 2020 research and innovation programme and EFPIA